Early responders to liraglutide 3.0mg as adjunct to diet and exercise from the SCALE

Aims: The SCALE Maintenance trial randomised adults with body mass index (BMI) > 30kg/m or BMI > 27kg/m with comorbidities, who lost >5% body weight during a 4 to 12 weeks, 12,000 to 1,400 kcal/day run‐in period prerandomisation to liraglutide 3.0mg or placebo adjunct to diet + exercise. This post hoc analysis compares outcomes in liraglutide 3.0mg early responders (ERs) vs early non‐responders (ENRs) (ERs vs ENRs; >5% vs 5%: 73.1% vs 11.8%; >10%: 47.2% vs 0%; >15%: 20.4 vs 0%) and similar improvements in car‐diometabolic risk factors were observed in ERs vs ENRs. AEs were reported in 92.7% ERs vs 91.0% ENRs. Serious AEs were 4.9% vs 0.0% and gastrointestinal AEs 78.9% vs 62.7% for ERs vs ENRs, respectively. Conclusion: Among those completing 56‐week treatment (following >5% weight loss), liraglutide 3.0mg ERs achieved greater weight loss than ENRs.